Search KRMD
KORU Medical Systems, Inc.
Nasdaq · CIK 704440
Last close2.96
Daily change-0.06 (-1.99%)
10 Years gain+596.47%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
KRMD · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
72.1Momentum
100.0Acceleration
100.0Confidence
83.0Annual Revenue15
Quarterly Revenue54
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.4 / 25
Quality20.9 / 25
Capital Efficiency9.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics3.9 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 14.5216 percentage points.
ROIC expansionROIC improved by 20.6284 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 7.6718%.
Key Metrics
Revenue Growth TTM28.93%OK
Revenue CAGR 3Y13.81%OK
Gross Margin62.64%OK
Operating Margin-3.19%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-8.58%OK
Incremental Operating Margin 3Y40.03%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y7.67%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $41.13M | $25.60M | -$2.97M | $462,405.00 | -$470,112.00 | 62.26% | -7.23% | -1.14% | -30.48% | 46.19M |
| 2025 FY Dec 31, 2024 | $33.65M | $21.33M | -$6.45M | -$319,718.00 | -$1.62M | 63.4% | -19.16% | -4.81% | -63.24% | 45.8M |
| 2024 FY Dec 31, 2023 | $28.52M | $16.71M | -$10.27M | -$4.89M | -$5.68M | 58.59% | -36.01% | -19.9% | -71.2% | 45.6M |
| 2023 FY Dec 31, 2022 | $27.90M | $15.37M | -$10.78M | -$5.40M | -$8.17M | 55.09% | -38.65% | -29.27% | -67.91% | 45M |
| 2022 FY Dec 31, 2021 | $23.49M | $13.77M | -$7.03M | -$4.32M | -$4.67M | 58.62% | -29.93% | -19.86% | -55.51% | 44.39M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $44.41M | sum latest 4 fiscal quarters Revenue | OK | 0001161697-26-000189, 0001161697-25-000372 |
| Revenue Growth TTM | 28.93% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001161697-26-000189, 0001161697-25-000372 |
| Revenue CAGR 3Y | 13.81% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001161697-26-000052 |
| Revenue CAGR 5Y | 11.21% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001161697-26-000052 |
| Gross Profit CAGR 3Y | 18.55% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001161697-26-000052 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001161697-26-000189, 0001161697-25-000372 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 62.64% | Gross Profit / Revenue | OK | 0001161697-26-000189, 0001161697-25-000372 |
| Operating Margin | -3.19% | Operating Income / Revenue | OK | 0001161697-26-000189, 0001161697-25-000372 |
| ROIC | -8.58% | NOPAT / Average Invested Capital | OK | 0001161697-26-000189, 0001161697-25-000372 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001161697-26-000189 |
| Current Ratio | 2.72x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.90 | Revenue / Diluted Shares | OK | 0001161697-26-000189, 0001161697-25-000372 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |